Tango Therapeutics, Inc.
TNGX
Rankning i aktier
#4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aktiekurs
$27.18
Senast synkroniserad: 2026-07-31
Marknadsvärde
$3.38B
Förändring (1 dag)
-1.41%
Förändring (1 år)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Historik för aktiesplit för Tango Therapeutics, Inc. (TNGX)
Aktien Tango Therapeutics, Inc. (symbol: TNGX) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En TNGX-aktie köpt före Oct 21, 2026 motsvarar nu 0 TNGX-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En TNGX-aktie köpt före Oct 21, 2026 motsvarar nu 0 TNGX-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
